Medicamen Biotech

Medicamen Biotech Current Liabilities

The Current Liabilities of Medicamen Biotech (MEDICAMEQ.NS) as of Oct 19, 2026 is 879.20 M INR. In the previous year, Current Liabilities was 786.87 M INR — a change of 11.73% (higher).

Current Liabilities

879.20 MINR

YoY

11.73%

Last updated:

Current Liabilities of Medicamen Biotech is 2026 879.20 M INR. Current Liabilities of Medicamen Biotech was 2025 786.87 M INR. It decreases by 11.73% higher compared to the previous year.

The Medicamen Biotech Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
310.00 M INR
Jan 1, 2020
370.13 M INR
Jan 1, 2021
501.64 M INR
Jan 1, 2022
632.43 M INR
Jan 1, 2023
760.10 M INR
Jan 1, 2024
807.87 M INR
Jan 1, 2025
786.87 M INR
Jan 1, 2026
879.20 M INR
The Medicamen Biotech Current Liabilities history
YEARCurrent LiabilitiesYoY
879.20 MINR+11.73%
786.87 MINR-2.60%
807.87 MINR+6.28%
760.10 MINR+20.19%
632.43 MINR+26.07%
501.64 MINR+35.53%
370.13 MINR+19.40%
310.00 MINR-16.89%
373.00 MINR-12.07%
424.20 MINR+16.60%
363.81 MINR-18.69%
447.43 MINR+4.14%
429.65 MINR+10.82%
387.70 MINR-18.17%
473.79 MINR-2.32%
485.03 MINR+29.09%
375.74 MINR+26.28%
297.54 MINR-16.33%
355.62 MINR+14.79%
309.79 MINR+51.66%
204.27 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medicamen Biotech Stock analysis

What does Medicamen Biotech do? Medicamen Biotech Ltd, based in New Delhi, India, operates in the Health Care sector, specifically within Pharmaceuticals. The company manufactures and markets diverse pharmaceutical formulations, including oral solids, liquids, ointments, and injectables for both non-oncology and oncology treatments. It focuses on oncology therapeutics, cardiology, central nervous system disorders, diabetology, and pain management. With 388 employees, Medicamen Biotech produces a range of products such as tablets, capsules, syrups, and specialized oncology drugs like Abiraterone acetate and Imatinib mesylate. Medicamen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medicamen Biotech stock

Current Liabilities of Medicamen Biotech is 879.20 M INR in 2026.

Current Liabilities of Medicamen Biotech changed from 786.87 M INR to 879.20 M INR, representing a 11.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Medicamen Biotech since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Medicamen Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Medicamen Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Medicamen Biotech